Sales grew 1% year on year for the 1H. In terms of the operating income analysis, manufacturing cost reductions and price reductions were nearly equivalent. While a sales volume increase had a positive effect of ¥0.5 billion, SG&A was ¥1.5 billion. Although the diagnostic ultrasound system business is positioned as an area to be reinforced as a pillar for future growth, the current increase in sales was not sufficient to compensate for the increase in upfront R&D and SG&A expenses in this area. This area is expected to make concrete contributions to sales and profits from the 2H and onward.